BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kerendia (Finerenone) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Kerendia (Finerenone)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06954090-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT06954090)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: Urinary Proteomics to Guide Early Intervention to Prevent Complications
  in Type 2 Diabetes - a Feasibility Study\nEstimated primary completion: 3
 0 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fine
 renone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06954090
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235891-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07235891)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: Retinal Protective Effects of Novel Finerenone in Patients With Chronic
  Kidney Disease\nEstimated primary completion: 20 December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07235891
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07026539-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07026539)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage
  in Patients With Type 2 Diabetes.\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0702
 6539
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07849348-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Kerendia (Finerenone): Phase na readout est. (NCT07849348)
DESCRIPTION:Kerendia (Finerenone)\, phase na\, Chronic Kidney Disease.\nStu
 dy: Study on the Efficacy and Safety of Initial Combination of Finerenone 
 and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by
  Chronic Kidney Disease With Albuminuria\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/finereno
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7849348
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688928-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Kerendia (Finerenone): Phase na readout est. (NCT07688928)
DESCRIPTION:Kerendia (Finerenone)\, phase na.\nStudy: Efficacy and Safety o
 f Finerenone Compared to Spironolactone in Treatment of Primary Aldosteron
 ism\nEstimated primary completion: March 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07688928
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06059664-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Kerendia (Finerenone): Phase 2 readout est. (NCT06059664)
DESCRIPTION:Kerendia (Finerenone)\, phase 2.\nStudy: The EFfect of FinEreno
 ne in Kidney TransplantiOn Recipients: The EFFEKTOR Study\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/finerenone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06059664
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537088-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07537088)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: Efficacy and Safety of Triple Therapy With Dulaglutide\, SGLT2 Inhibito
 rs\, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kid
 ney Disease\nEstimated primary completion: April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07537088
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05196035-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT05196035)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: A Study to Learn More About How Well the Study Treatment Finerenone Wor
 ks\, How Safe it is\, How it Moves Into\, Through\, and Out of the Body\, 
 and the Effects it Has on the Body When Taken With an ACE Inhibitor or Ang
 iotensin Receptor Blocker in Children With Chronic Kidney Disease and Prot
 einuria\nEstimated primary completion: 10 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05196035
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678151-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Kerendia (Finerenone): Phase na readout est. (NCT07678151)
DESCRIPTION:Kerendia (Finerenone)\, phase na.\nStudy: Finerenone and Empagl
 iflozin Combination in Obesity With Hypertension: A 12-Week Prospective\, 
 Parallel-design\, Double-blind\, Randomized\, Placebo-controlled Trial\nEs
 timated primary completion: 30 April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07678151
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598864-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07598864)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With 
 Type 2 Diabetes"\nEstimated primary completion: 1 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07598864
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155694-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07155694)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: Role of Finerenone in African American Veterans With Diabetic Kidney Di
 sease\nEstimated primary completion: July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07155694
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830940-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270925
DTEND;VALUE=DATE:20270926
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07830940)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Heart Failure.\nStudy: Finere
 none and Cardiac Remodeling in HFpEF\nEstimated primary completion: 25 Sep
 tember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/finereno
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7830940
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356388-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07356388)
DESCRIPTION:Kerendia (Finerenone)\, phase 3.\nStudy: FINEPKT - Finerenone i
 n Proteinuria Patients After Kidney Transplan\nEstimated primary completio
 n: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fi
 nerenone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07356388
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315191-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07315191)
DESCRIPTION:Kerendia (Finerenone)\, phase 4.\nStudy: Finerenone Therapy for
  Pediatric HSPN With Mild Proteinuria\nEstimated primary completion: 31 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/finerenon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 315191
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583173-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07583173)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Heart Failure.\nStudy: Effect
  of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF
  Patients\nEstimated primary completion: 31 October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07583173
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667517-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07667517)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chroni
 c Kidney Disease\nEstimated primary completion: 31 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07667517
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008197-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06008197)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Determine the Efficacy and Safety of Finerenone on Morbidity and Mort
 ality Among Hospitalized Heart Failure Patients\nEstimated primary complet
 ion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/f
 inerenone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06008197
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06024746-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06024746)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combina
 tion in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)\nEstima
 ted primary completion: November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06024746
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815509-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Kerendia (Finerenone): Phase 2 readout est. (NCT07815509)
DESCRIPTION:Kerendia (Finerenone)\, phase 2.\nStudy: Finerenone for Prematu
 re Ovarian Insufficiency (POI)\nEstimated primary completion: December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07815509
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397650-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07397650)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Heart Failure.\nStudy: Effica
 cy and Safety With Early Treatment of Finerenone in Hospitalized Patients 
 With Heart Failure\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07397650
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181135-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07181135)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic 
 Kidney Disease Not Using Renin-angiotensin-system Inhibitors\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07181135
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906081-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Kerendia (Finerenone): Phase 2 readout est. (NCT06906081)
DESCRIPTION:Kerendia (Finerenone)\, phase 2.\nStudy: Finerenone Treatment f
 or Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study\nEstim
 ated primary completion: January 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06906081
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585526-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Kerendia (Finerenone): Phase na readout est. (NCT07585526)
DESCRIPTION:Kerendia (Finerenone)\, phase na\, Chronic Kidney Disease.\nStu
 dy: Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated 
 Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascit
 es in Prevention of Chronic Kidney Disease.\nEstimated primary completion:
  31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/finer
 enone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07585526
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239570-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07239570)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients 
 With Chronic Kidney Disease\nEstimated primary completion: June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07239570
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799519-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Kerendia (Finerenone): Phase 2 readout est. (NCT07799519)
DESCRIPTION:Kerendia (Finerenone)\, phase 2.\nStudy: Finerenone After Cathe
 ter Ablation to Reduce Atrial Fibrillation Recurrence\nEstimated primary c
 ompletion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/finerenone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07799519
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05457283-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT05457283)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: A Study to Learn More About How Safe the Study Treatment Finerenone is 
 in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor 
 Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Ye
 ars of Age With Chronic Kidney Disease and Proteinuria\nEstimated primary 
 completion: 7 August 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/finerenone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05457283
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07442448-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07442448)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Heart Failure.\nStudy: Invest
 igation on the Impact of Finerenone on Myocardial Remodeling in Patients W
 ith Diabetic Kidney Disease and Heart Failure\nEstimated primary completio
 n: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fin
 erenone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07442448
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775482-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Kerendia (Finerenone): Phase na readout est. (NCT07775482)
DESCRIPTION:Kerendia (Finerenone)\, phase na.\nStudy: Finerenone for AKI: a
  Multicenter\, Randomized\, Placebo-Controlled Feasibility Pilot Trial\nEs
 timated primary completion: January 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07775482
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775846-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07775846)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy\nEstimat
 ed primary completion: 28 February 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07775846
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547878-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Kerendia (Finerenone): Phase 4 readout est. (NCT07547878)
DESCRIPTION:Kerendia (Finerenone)\, phase 4\, Chronic Kidney Disease.\nStud
 y: Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therap
 ies (RAPID-CKD)\nEstimated primary completion: 31 March 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07547878
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082063-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06082063)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: Multif
 actorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes\
 nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06082063
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188805-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07188805)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Learn More About How Well Finerenone Works\, How Safe it is\, and How
  it Moves Into\, Through\, and Out of the Body Compared to Placebo When Ta
 ken With Standard Treatment in Children With Heart Failure and Left Ventri
 cular Systolic Dysfunction\nEstimated primary completion: 30 November 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07188805
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594145-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Kerendia (Finerenone): Phase 2 readout est. (NCT07594145)
DESCRIPTION:Kerendia (Finerenone)\, phase 2\, Heart Failure.\nStudy: Precis
 ion T1D Platform - New Therapies for Cardio-Renal Complications\nEstimated
  primary completion: 31 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07594145
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058585-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06058585)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: The Chronic Kidney Disease Adaptive Platform Trial Investigating Variou
 s Agents for Therapeutic Effect\nEstimated primary completion: 31 December
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0605858
 5
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575672-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07575672)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: Finere
 none in Patients Undergoing Transcatheter Aortic Valve Implantation With H
 eart Failure\nEstimated primary completion: 31 December 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07575672
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07270367-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07270367)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: Finere
 none and Cardiac Remodeling\nEstimated primary completion: December 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07270367
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192952-661@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07192952)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Learn More About How Safe Finerenone is\, When it is Taken for a Long
 er Time With Standard Treatment\, in Children and Young Adults With Heart 
 Failure and Left Ventricular Systolic Dysfunction\nEstimated primary compl
 etion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/finerenone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07192952
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
